Mkts

Scinai Immunotherapeutics Ltd.

NASDAQ: SCNI
$0.40+0.00 (+1.02%)
As of Nov 16, 4:00 PM ET

Key statistics

Day range
0.390.43
52-week range
0.3913.00
Today
Open0.39
Previous close0.40
Volume—
Valuation
Market cap541.3K
P/E ratio—
EPS (TTM)-0.01
Income & risk
Dividend / yield—
Beta2.22
Avg volume1.56M
Discussion

SCNI News

Stories mentioning SCNI from around the web — every one is an open thread, so give it a like or add your take.

All news →

Loading news…

Financial statements

Financial statements

As filed, straight from the 10-Q — up to 19 years of history, free, with every line item chartable.

Line itemQ1 '23Mar 31Q1 '22Mar 31
Income Statement
Revenue
Cost of Goods Sold
Gross Profit0.000.00
Operating Expenses
Research & Development1,9951,163
Sales General & Admin
Total Operating Expenses
Operating Income (Loss)(3,186)(2,615)
Interest Income
Interest Expense
Other Expense
Pretax Income
Tax Provision
Net Income (Loss)(3,515)(2,475)
Earnings Per Share (Basic)(0.00)(0.00)
Earnings Per Share (Diluted)(0.00)(0.00)
Weighted Average Shares Outstanding (Basic)1,295,257744,711
Weighted Average Shares Outstanding (Diluted)1,295,257744,711

Scroll the table sideways for older periods — the line-item column and the period header stay put. Hover a row and use the chart handle to plot it over the full history.

Key facts

About SCNI

Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) is a stock listed on the Nasdaq Stock Market under the ticker symbol SCNI. It last traded at $0.4000 (Nov 16, 2026, 4:00 PM ET), up 1.0% on the day. That gives Scinai Immunotherapeutics a market capitalisation of $541.3K.

Over the past 52 weeks SCNI has traded between $0.3900 and $13.00.

For the quarter ended Mar 31, 2023 it reported a net loss of $3.5M.

Last 2 quarters
Quarter endedRevenueNet income
Mar 31, 2023—-$3.5M
Mar 31, 2022—-$2.5M

From Scinai Immunotherapeutics’s quarterly (10-Q) filings, in US dollars.

Latest News

Market news from around the web — every story is an open thread, so give it a like or add your take.

All news →

Loading news…